Npm1-Mutated Acute Myeloid Leukemia

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the potential benefit of ceasing venetoclax-based therapy after remission in patients with acute myeloid leukemia.

The FDA granted fast track designation to SNDX-5613 for the treatment of adults and children with relapsed or refractory acute myeloid leukemia or acute lymphoblastic leukemia with certain genetic markers.